Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …

We recommend a new term,“primary age-related tauopathy”(PART), to describe a pathology
that is commonly observed in the brains of aged individuals. Many autopsy studies have …

Aging, hypertension, diabetes, hypoxia/obstructive sleep apnea (OSA), obesity, vitamin
B12/folate deficiency, depression, and traumatic brain injury synergistically promote diverse …

Recent epidemiological and clinico-pathological data indicate considerable overlap
between cerebrovascular disease (CVD) and Alzheimer's disease (AD) and suggest …

As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …

White matter hyperintensities are associated with increased risk of dementia and cognitive
decline. The current study investigates the relationship between white matter …

Hippocampal atrophy, as evidenced using magnetic resonance imaging (MRI), is one of the
most validated, easily accessible and widely used biomarkers of Alzheimer's disease (AD) …

Older adults with lower education are at greater risk for dementia. It is unclear which brain
changes lead to these outcomes. Longitudinal imaging-based measures of brain structure …